This Article Abstract Full Text (PDF) All Versions of this Article: 47/4/711    most recent 01.HYP.0000208840.30778.00v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsusaka, H. Articles by Tsutsui, H. Search for Related Content PubMed PubMed Citation Articles by Matsusaka, H. Articles by Tsutsui, H. Related Collections Structure Remodeling Animal models of human disease Gene expression Genetically altered mice Hypertrophy Myocardial cardiomyopathy disease Related Article

(Hypertension. 2006;47:711.)
© 2006 American Heart Association, Inc.

Original Articles

Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload

Hidenori Matsusaka; Tomomi Ide; Shouji Matsushima; Masaki Ikeuchi; Toru Kubota; Kenji Sunagawa; Shintaro Kinugawa; Hiroyuki Tsutsui

From the Department of Cardiovascular Medicine (H.M., T.I., S.M., M.I., T.K., K.S.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; and Department of Cardiovascular Medicine (S.K., H.T.), Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Correspondence to Hiroyuki Tsutsui, Dept of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan. E-mail htsutsui{at}med.hokudai.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Matrix metalloproteinases (MMPs) play an important role in the extracellular matrix remodeling. Experimental and clinical studies have demonstrated that MMP 2 and 9 are upregulated in the dilated failing hearts and involved in the development and progression of myocardial remodeling. However, little is known about the role of MMPs in mediating adverse myocardial remodeling in response to chronic pressure overload (PO). We, thus, hypothesized that selective disruption of the MMP 2 gene could ameliorate PO-induced cardiac hypertrophy and dysfunction in mice. PO hypertrophy was induced by transverse aortic constriction (TAC) in male MMP 2 knockout (KO) mice (n=10) and sibling wild-type (WT) mice (n=9). At 6 weeks, myocardial MMP 2 zymographic activity was 2.4-fold increased in WT+TAC, and this increase was not observed in KO+TAC, with no significant alterations in other MMPs (MMP 1, 3, 8, and 9) or tissue inhibitors of MMPs (1, 2, 3, and 4). TAC resulted in a significant increase in left ventricular (LV) weight and LV end-diastolic pressure (EDP) with preserved systolic function. KO+TAC mice exerted significantly lower LV weight/body weight (4.2±0.2 versus 5.0±0.2 mg/g; P<0.01), lung weight/body weight (4.9±0.2 versus 6.2±0.4 mg/g; P<0.01), and LV end-diastolic pressure (4±1 versus 10±2 mm Hg; P<0.05) than WT+TAC mice despite comparable aortic pressure. KO+TAC mice had less myocyte hypertrophy (cross-sectional area; 322±14 versus 392±14 µm²; P<0.01) and interstitial fibrosis (collagen volume fraction; 3.3±0.5 versus 8.2±1.0%; P<0.01) than WT+TAC mice. MMP 2 plays an important role in PO-induced LV hypertrophy and dysfunction. The inhibition of MMP 2 activation may, therefore, be a useful therapeutic strategy to manage hypertensive heart disease.

Key Words: hypertrophy • heart failure • fibrosis • extracellular matrix • hypertension, experimental • myocardium

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Left ventricular (LV) hypertrophy is an adaptive process that compensates for pressure overload (PO) caused by hypertension or valvular heart disease, such as aortic stenosis. This remodeling process consists of hypertrophic changes of cardiac myocytes and abnormalities of the extracellular matrix (ECM) network, which are both responsible for changes in systolic and diastolic function.¹

The dynamic synthesis and breakdown of ECM proteins play an important role in adverse myocardial remodeling. In particular, the increased expression and activation of the matrix metalloproteinases (MMPs) have been shown in various forms of heart failure and implicated in the process of myocardial remodeling that is characteristic of developing heart failure.² Despite a number of studies implicating MMPs in cardiac pathophysiology, little is known about the role of MMP in the development of myocardial remodeling in response to chronic PO. MMP 2 and 9 expression has been shown to be enhanced in pressure-overloaded cardiac hypertrophy in spontaneously hypertensive rats³ and in Dahl salt-sensitive hypertensive rats.⁴ Similar upregulation of MMPs has been also observed in human pressure-overloaded hearts because of aortic stenosis.⁵ Recently, Heymans et al⁶ have demonstrated that MMP 9 is involved in cardiac remodeling associated with hypertension. However, MMP-9 is mainly expressed in such infiltrating inflammatory cells as neutrophils and macrophages.⁷ Conversely, MMP 2 is ubiquitously distributed in cardiac myocytes and fibroblasts.⁸ Therefore, MMP 2 may also play an important role in the development and progression of myocardial remodeling in response to PO. However, no previous studies have yet determined the pathophysiological significance of MMP 2 in this disease state.

In the present study, we evaluated the effects of a targeted deletion of the MMP 2 gene on both LV structural and functional alterations during pressure-overloaded cardiac hypertrophy. To ensure selective and long-term complete inhibition of MMP 2, we used MMP 2 knockout (KO) mice.^9–11 The most effective way to evaluate the contribution of the specific MMP and obtain the direct evidence for a role of MMP is through gene manipulation instead of MMP inhibitor.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Experimental Animals
The study was approved by our Institutional Animal Research Committee and conformed to the animal care guidelines of the American Physiological Society. We used the progeny of homozygous breeding pairs of C57BL/6J mice with targeted disruption of MMP 2 ranging in age from 11 to 14 weeks old.¹⁰ The mutation heterozygous mice were obtained by crossing the chimeras to C57BL/6J mice. Heterozygotes were backcrossed to C57BL/6J 1 to 5 times and then crossed to obtain the mutation homozygous mice. The original breeding pairs used to develop the mice for this study were obtained from Dr Shigeyoshi Itohara (Laboratory for Behavioral Genetics, RIKEN, Tsukuba, Japan).

Transverse Aortic Constriction
Transverse aortic constriction (TAC) was performed in male MMP 2 KO and sibling wild-type (WT) mice as described previously.¹² Briefly, after anesthetizing by tribromoethanol/amylene hydrate (Avertin; 2.5% weight/volume, 8 µL/g IP), mice were intubated and ventilated, and a thoracotomy was performed via the second intercostal space at the left upper sternal border. The transverse aortic arch was ligated between the innominate and left common carotid arteries with an overlying 28-gauge needle, which, after removal of the needle, left a reproducible discrete region of stenosis. Sham-operated mice underwent a similar procedure without ligation of the aorta.

Tail clips and a PCR protocol to confirm the genotype were performed by a group of investigators. Next, TAC was induced in these mice by another subset of investigators, who were not informed of the genotyping results. This assignment procedure was performed using numeric codes to identify the animals.

MMPs and Tissue Inhibitors of MMPs
First, the myocardial MMP levels, including MMP 2 and MMP 9, were determined in the left ventricle (LV) using gelatin zymography as described previously.¹³ The LV myocardial samples were homogenized (30-s bursts) in 1 mL of an ice-cold extraction buffer containing cacodylic acid (10 mmol/L), NaCl (0.15 mol/L), ZnCl₂ (20 mmol/L), NaN₂ (1.5 mmol/L), and 0.01% Triton X-100 (pH 5.0). The homogenate was then centrifuged (4°C, 10 minutes, 10 000g) and the supernatant decanted and saved on ice. The pH levels of the samples were adjusted to 7.5 using Tris (1 mol/L). The final protein concentration of the myocardial extracts was determined using a standardized colorimetric assay. The extracted samples were then aliquoted and stored at –80°C until the time of assay. The myocardial extracts were then directly loaded onto electrophoretic gels (SDS-PAGE) containing 1 mg/mL of gelatin under nonreducing conditions. The myocardial extracts at a final protein content of 5 µg were loaded onto the gels using a 3:1 sample buffer (10% SDS, 4% sucrose, 0.25 mol/L Tris-Cl, and 0.1% bromophenol blue pH 6.8]). The gels were run at 15 mA/gel through the stacking phase (4%) and at 20 mA/gel for the separating phase (10%), whereas the running buffer temperature was maintained at 4°C. After SDS-PAGE, the gels were washed twice in 2.5% Triton X-100 for 30 minutes each, rinsed in water, and incubated for 24 hours in a substrate buffer at 37°C (50 mmol/L Tris-HCl, 5 mmol/L, CaCl₂, and 0.02% NaN₃ [pH 7.5]). After incubation, the gels were stained with Coomassie brilliant blue R-250. The zymograms were digitized, and the size-fractionated bands, which indicated the MMP proteolytic levels, were measured by the integrated optical density in a rectangular region of interest.

Next, the mRNA levels of myocardial MMPs including MMP 1, 2, 3, 8, and 9 as well as tissue inhibitors of MMPs (TIMPs) including TIMP 1, 2, 3, and 4 were determined by multiprobe ribonuclease protection assay (RiboQuant, PharMingen). Each value was normalized to that of glyceraldehydes-3-phosphate-dehydrogenase in each template set as an internal control, followed by calculation as a ratio to WT+Sham. The amount of tissue was limited in mice and, thus, tissue needed to be divided so that all of the biochemical analyses could be performed.

Echocardiographic and Hemodynamic Measurements
Echocardiographic studies were performed under light anesthesia with tribromoethanol/amylene hydrate (Avertin; 2.5% weight/volume, 8 µL/g IP) and spontaneous respiration as described previ-ously.¹⁴ A 2D parasternal short-axis view of the LV was obtained at the level of the papillary muscles. In general, the best views were obtained with the transducer lightly applied to the mid-upper left anterior chest wall. The transducer was then gently moved cephalad or caudad and angulated until desirable images were obtained. After confirming that the imaging was on axis (based on roundness of the LV cavity), 2D targeted M-mode tracings were recorded at a paper speed of 50 mm/s. Two consecutive heartbeats of each frame were analyzed to measure the wall thickness and end-diastolic (EDD) and end-systolic (ESD) internal dimensions of the LV. LV fractional shortening (FS) was calculated as LV EDD minus LV ESD normalized for LV EDD and was taken as an index of LV systolic performance. Echocardiographic LV mass was calculated according to the standard cube formula as described previously.¹⁵ Our previous validation study has shown that the intraobserver and interobserver variabilities of our echocardiographic measurements for LV cavity dimensions and FS were small, and measurements made in the same animals on separate days were highly reproducible.¹⁴ Next, a 1.4-Fr micromanometer-tipped catheter (Millar) was inserted into the right carotid artery and then was advanced into the LV to measure the LV pressures. Arterial blood pressure and heart rate were also measured with the use of a noninvasive tail-cuff system (BP-98A, Softron).¹⁶

Organ Weight and Histopathology
After in vivo echocardiographic and hemodynamic studies, the heart and lung were excised, and their weights were determined. The heart was dissected into the right and left ventricles, including the septum. From the mid-LV transverse sections, 5-µm sections were cut and stained with hematoxylin/eosin and Masson’s trichrome to determine the myocyte cross-sectional area and collagen volume fraction. To measure the myocyte cross-sectional area, each section was photographed using a microscope and magnified (final magnification: x750). Connective tissue and muscle areas were identified, and the profile margin of 30 to 40 myocytes cut into cross-sections was manually traced and digitized. The digitized profiles were transferred to a personal computer that calculated the area. Three to 4 fields were randomly selected from 2 to 3 coronal sections of each heart. Thus, 100 to 200 myocytes were measured for each animal, and the mean myocyte cross-sectional area was calculated.¹⁷ Collagen volume fraction was measured at 5 to 7 fields for each heart.¹⁸ Within each field, segments representing connective tissue and myocyte were identified and manually traced by using a digitizing pad with a computer to calculate the traced area. Collagen volume fraction was then calculated for the heart as the sum of all of the connective tissue areas divided by the sum of all of the connective tissue and muscle areas in all fields. Collagen surrounding intramyocardial coronary arteries was excluded from the analysis.

Statistical Analysis
All of the data are expressed as the mean±SEM. Between-group comparisons of the means were performed by 1-way ANOVA, followed by t tests. The Bonferroni’s correction was done for multiple comparisons of the means.

	Results

Top Abstract Introduction Methods Results Discussion References

 
MMPs and TIMPs
At 6 weeks of TAC, the zymographic MMP 2 levels increased by 2.4-fold compared with WT+Sham mice (Figure 1). As expected, MMP 2 activity was not detected in KO+Sham and KO+TAC mice. Importantly, the MMP 9 zymographic levels did not differ between WT+TAC and KO+TAC.

View larger version (34K): [in this window] [in a new window]   Figure 1. (A) Representative gelatin zymography of the LV from 4 groups of WT+Sham, KO+Sham, WT+TAC, and KO+TAC mice. (B and C) Densitometric analysis of MMP-2 (B) and MMP-9 (C) zymographic activity (n=3 each). Data are expressed as the ratio to WT+Sham values run concurrently on the same gel. Values are mean±SEM. *P<0.05 vs WT+Sham; P<0.01 vs WT+TAC.

Again, the MMP 2 mRNA levels significantly increased in the WT+TAC compared with WT+Sham (Figure 2). This increase was not observed in KO+TAC. These results were consistent with those observed in gelatin zymography (Figure 1). Other MMPs, including MMP 1, 3, 8, and 9, were not altered in these mice (Figure 2). The changes of TIMPs (TIMP 1, 2, 3, and 4) were also comparable between WT+TAC and KO+TAC.

View larger version (45K): [in this window] [in a new window]   Figure 2. (A) Representative image of myocardial gene expression of MMPs and TIMPs. (B) Densitometric analysis of MMP and TIMP gene expression from WT+TAC (n=5) and KO+TAC (n=4). Each value was normalized to that of glyceraldehydes-3-phosphate-dehydrogenase in each template set as an internal control and expressed as the ratio to WT+Sham (n=3). Values are mean±SEM. *P<0.01 vs WT+Sham; P<0.01 vs WT+TAC.

Echocardiography
The presence or absence of MMP 2 gene did not affect baseline heart rate or echocardiographic parameters in Sham mice (Table 1). TAC significantly increased LV wall thickness (Table 1) and echocardiographic LV mass (Figure 3) without affecting LV diameters or FS in WT+TAC. These LV hypertrophic changes in WT+TAC were significantly ameliorated in KO+TAC.

View this table: [in this window] [in a new window]   TABLE 1. Echocardiographic Data

View larger version (28K): [in this window] [in a new window]   Figure 3. Echocardiographic LV mass from 4 groups of WT+Sham (n=6), KO+Sham (n=6), WT+TAC (n=9), and KO+TAC (n=10) mice. Values are mean±SEM. *P<0.01 vs WT+Sham; P<0.05, P<0.01 vs KO+Sham; P<0.01 vs WT+TAC.

Hemodynamics
LV systolic pressure was markedly elevated by TAC (Table 2). However, there was no significant difference in LV systolic pressure between WT+TAC and KO+TAC mice. LV EDP increased significantly in WT+TAC mice, and this increase was significantly attenuated in KO+TAC mice.

View this table: [in this window] [in a new window]   TABLE 2. Hemodynamic Data

Organ Weights
In agreement with echocardiographic LV mass (Figure 3), TAC increased LV weight in WT mice (Figure 4A). Furthermore, in accordance with LV EDP, lung weight/body weight, indicative of pulmonary congestion, increased significantly in WT+TAC (Figure 4B). In KO+TAC, both increased LV and lung weights were significantly reduced.

View larger version (29K): [in this window] [in a new window]   Figure 4. LV weight and lung weight from 4 groups of WT+Sham (n=6), KO+Sham (n=6), WT+TAC (n=9), and KO+TAC (n=10) mice. Values are mean±SEM. *P<0.01 vs WT+Sham; P<0.01 vs KO+Sham; P<0.01 vs WT+TAC.

Histopathology
Masson’s trichrome staining showed the increase in myocyte size and interstitial collagen volume fraction in WT+TAC mice compared with WT+Sham mice (Figure 5). The selective disruption of the MMP 2 gene significantly ameliorated myocyte hypertrophy and interstitial fibrosis by TAC. Similarly, picrosirius staining also demonstrated collagen deposition in the interstitial areas in LV sections from WT+TAC mice and the amelioration of interstitial fibrosis in KO+TAC mice (data not shown).

View larger version (59K): [in this window] [in a new window]   Figure 5. (A) Representative high-power photomicrographs of LV cross-sections stained with Masson’s trichrome from 4 groups of WT+Sham, KO+Sham, WT+TAC, and KO+TAC mice. Scale bar, 10 µm. (B) Summary data of myocyte cross-sectional area (top) and collagen volume fraction (bottom) by the histomorphometric analysis of LV tissue sections from 4 groups of WT+Sham (n=4), KO+Sham (n=4), WT+TAC (n=5), and KO+TAC (n=5) mice. Values are mean±SEM. *P<0.01 vs WT+Sham; P<0.01 vs KO+Sham; P<0.01 vs WT+TAC.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In the present study, we demonstrated that the selective disruption of the MMP 2 gene ameliorated LV remodeling, such as myocyte hypertrophy and interstitial fibrosis in TAC mice, thus providing direct evidence that MMP 2 is involved in mediating PO-induced cardiac hypertrophy. These beneficial effects of MMP 2 inhibition occurred without affecting hemodynamics.

Upregulation of MMP 2 in PO Hypertrophy
The present study demonstrated that the MMP 2 gene expression and gelatinolytic activities were upregulated in the myocardium during PO (Figures 1 and 2). These findings, coupled with past reports, suggest that an increase in myocardial MMP levels is a fairly uniform event in myocardial remodeling.^2,3,6,19,20 Although the mechanisms responsible for this activation remain to be determined, cellular constituents of cardiac muscle, including fibroblasts, inflammatory cells, and myocytes, are known to be capable of expressing MMP 2 in response to specific stimuli, including mechanical stress.^9,21

Role of MMP 2 in PO Hypertrophy
Alterations in the expression and activity of MMP 2 have been demonstrated in a number of pathophysiological conditions, such as myocardial infarction (MI) and heart failure. Our previous study¹⁰ and a recent study by Matsumura et al²² have demonstrated that the inhibition of MMP 2 activity improves the survival rate after acute MI by preventing cardiac rupture and delays after MI remodeling. A recent study by Wang et al²³ has shown that cardiac-specific, constitutively active MMP 2 expression leads to impaired contraction and diminished responses to inotropic stimulation, indicating that MMP 2 can directly impair cardiac function in the absence of superimposed injury.

Broad-spectrum pharmacological inhibition of MMPs significantly attenuated myocardial remodeling associated with chronic volume overload³ or hypertension.¹⁹ However, the most effective way to evaluate the contribution of the specific MMP and to obtain the direct evidence for a role of MMP in myocardial remodeling and failure is through such gene manipulation as that used in the present study. As expected, no MMP 2 expression was observed in the myocardium from KO mice in this study (Figures 1 and 2). Thus, the present study could investigate the effects of selective disruption of the MMP 2 gene on the development of myocardial hypertrophy induced by PO.

The most striking finding of the present study was the inhibition of myocardial hypertrophy in MMP 2 KO mice under PO (Figures 3 through 5). Our previous studies demonstrated the beneficial effects of MMP 2 deletion also on postinfarct LV remodeling and failure.¹⁰ Similar to the present study, both myocyte hypertrophy and interstitial collagen accumulation were ameliorated in the MMP 2–deficient mice after MI. Moreover, the present study is consistent with previous studies from other laboratories, which demonstrated the involvement of myocardial MMP in heart failure.^2,24,25 Therefore, the present study builds on these past reports by demonstrating that MMP inhibition attenuated myocardial remodeling that occurred also under PO.

The present study demonstrated that increased MMP 2 activity was associated with the interstitial fibrosis in pressure-overloaded LV and the selective inhibition of MMP 2, indeed, ameliorated these changes (Figure 5). Theoretically, an increase in MMP activity would result in a decrease in the MMP substrate, collagens, whereas an inhibition of MMP would result in an increase in collagens. However, in agreement with previous studies,¹⁰ an increase in MMP 2 activity was accompanied by increased fibrosis in our model of LV hypertrophy, which is probably because of the direct proteolysis of myocardial matrix components, as well as by facilitating a profibrotic response. In fact, the selective disruption of the MMP 2 gene did attenuate interstitial fibrosis. Although the present study could not provide the definite explanation for these paradoxical findings, this might be because of the fact that the total ECM collagen content is a complex function of both synthesis and degradation.

In addition to interstitial fibrosis, myocyte cellular hypertrophy was also ameliorated by the selective blockade of the MMP 2 gene (Figure 5), suggesting that myocardial induction of MMP 2 is involved in the development of myocyte hypertrophy during PO. Recently, Heymans et al⁶ demonstrated that MMP 9 gene inactivation reduced hypertrophic changes in cardiac myocytes during acute PO. These results suggest that there is an intimate link between MMPs and the myocyte hypertrophic process, which might be mediated, at least in part, by the tissue infiltration of inflammatory cells. However, the precise role of MMPs in the development of myocyte hypertrophy has not been fully explored. MMPs may be involved in a complex myocyte-matrix interaction, because the basement membrane components, collagen IV and laminin, are the substrates for MMP 2 and MMP 9.²⁶ Thus, increased MMP 2 activity within the myocardium can contribute to the discontinuity of the basement membrane, thereby disrupting the normal myocyte-matrix interface. The findings that MMP inhibition limited the degree of myocyte hypertrophy raise an issue requiring additional studies.

Limitations
There are several issues to be acknowledged as a limitation in this study. First, although in vivo assessment of LV function with echocardiography is feasible and reproducible in the mouse, it might still be difficult to interpret the indices of LV function. However, our validation study has shown that the intraobserver and interobserver variabilities of our echocardiographic measurements for LV dimensions and FS were small, and the measurements made in the same animals on separate days were highly reproducible.¹⁴ Therefore, our technique could be considered to allow for a noninvasive assessment of the LV structure and function. Second, the heart rate values in the present study (460 to 480 bpm) were lower than those (600 bpm) measured in conscious mice. Therefore, the LV size and function data might be greatly influenced by differences in anesthetic regimens and the experimental conditions, such as the heart rate. Third, MMP 9 was not increased in our model of PO hypertrophy. Although the present study could not provide the definite explanation for these results, they might be related to the small number of infiltrating inflammatory cells as neutrophils and macrophages, in which MMP 9 is mainly expressed, within the hypertrophied LV.

Perspectives
Diastolic dysfunction is an important factor contributing to the development of heart failure. One of the most common causes for diastolic heart failure is LV hypertrophy associated with hypertension. The present study demonstrated that MMP 2 inhibition reduced myocyte hypertrophy and interstitial fibrosis, which might contribute to a decrease in LV EDP and lung weight, an index of pulmonary congestion, without affecting LV systolic function. Therefore, although the present study did not directly evaluate the diastolic function itself, the reduction of LV EDP and lung congestion achieved with MMP 2 inhibition in this model is considered to be because of the attenuation of LV hypertrophy and the resultant improvement of diastolic function.

Conclusions
Chronic PO results in an initial cardiac hypertrophic response followed by progressive failure. Our findings provide the first direct evidence that MMP 2 is involved in mediating the adverse myocardial remodeling that occurs in response to a common form of hemodynamic overload. The beneficial effects of MMP 2 inhibition occurred in the absence of a decrease in systemic blood pressure. These findings suggest that the early institution of MMP 2 inhibition may have use in preventing the development of maladaptive myocardial remodeling in response to hypertension.

	Acknowledgments

 
This study was supported in part by grants from the Ministry of Education, Science and Culture (No. 12670676, 14370230, and 17390223). A part of this study was conducted in Kyushu University Station for Collaborative Research I and II.

Received November 28, 2005; first decision December 13, 2005; accepted January 3, 2006.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289: 194–202.[Abstract/Free Full Text]

2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002; 90: 520–530.[Abstract/Free Full Text]

3. Peterson JT, Hallak H, Johnson L, Li H, O’Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001; 103: 2303–2309.[Abstract/Free Full Text]

4. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation. 2004; 109: 2143–2149.[Abstract/Free Full Text]

5. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol. 2004; 44: 1609–1618.[Abstract/Free Full Text]

6. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005; 166: 15–25.[Abstract/Free Full Text]

7. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, Yue TL. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res. 2002; 54: 549–558.[Abstract/Free Full Text]

8. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000; 101: 1833–1839.[Abstract/Free Full Text]

9. Schubert A, Walther T, Falk V, Binner C, Loscher N, Kanev A, Bleiziffer S, Rauch T, Autschbach R, Mohr FW. Extracellular matrix gene expression correlates to left ventricular mass index after surgical induction of left ventricular hypertrophy. Basic Res Cardiol. 2001; 96: 381–387.[CrossRef][Medline] [Order article via Infotrieve]

10. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003; 285: H1229–H1235.[Abstract/Free Full Text]

11. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of ß-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997; 272: 22389–22392.[Abstract/Free Full Text]

12. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991; 88: 8277–8281.[Abstract/Free Full Text]

13. Matsusaka H, Ikeuchi M, Matsushima S, Ide T, Kubota T, Feldman AM, Takeshita A, Sunagawa K, Tsutsui H. Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289: H1858–H1864.[Abstract/Free Full Text]

14. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor- agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002; 106: 3126–3132.[Abstract/Free Full Text]

15. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol. 2002; 282: H1703–H1708.[Abstract/Free Full Text]

16. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25: 1111–1115.[Abstract/Free Full Text]

17. Ishibashi Y, Tsutsui H, Yamamoto S, Takahashi M, Imanaka-Yoshida K, Yoshida T, Urabe Y, Sugimachi M, Takeshita A. Role of microtubules in myocyte contractile dysfunction during cardiac hypertrophy in the rat. Am J Physiol. 1996; 271: H1978–H1987.[Medline] [Order article via Infotrieve]

18. Namba T, Tsutsui H, Tagawa H, Takahashi M, Saito K, Kozai T, Usui M, Imanaka-Yoshida K, Imaizumi T, Takeshita A. Regulation of fibrillar collagen gene expression and protein accumulation in volume-overloaded cardiac hypertrophy. Circulation. 1997; 95: 2448–2454.[Abstract/Free Full Text]

19. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002; 105: 1983–1988.[Abstract/Free Full Text]

20. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005; 112: 1136–1144.[Abstract/Free Full Text]

21. Nagatomo Y, Carabello BA, Coker ML, McDermott PJ, Nemoto S, Hamawaki M, Spinale FG. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol. 2000; 278: H151–H161.[Abstract/Free Full Text]

22. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005; 115: 599–609.[CrossRef][Medline] [Order article via Infotrieve]

23. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res. 2006; 69: 688–696.[Abstract/Free Full Text]

24. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999; 5: 1135–1142.[CrossRef][Medline] [Order article via Infotrieve]

25. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000; 106: 55–62.[Medline] [Order article via Infotrieve]

26. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274: 21491–21494.[Free Full Text]

Related Article:

Matrix Reloaded: The Matrix Metalloproteinase Paradox

Anna N. Panek and Michael Bader
Hypertension 2006 47: 640-641. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]

				A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition Circ Heart Fail, November 1, 2008; 1(4): 249 - 257. [Abstract] [Full Text] [PDF]

				N. Hedhli, P. Lizano, C. Hong, L. F. Fritzky, S. K. Dhar, H. Liu, Y. Tian, S. Gao, K. Madura, S. F. Vatner, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1385 - H1393. [Abstract] [Full Text] [PDF]

				J. A. Zavadzkas, R. A. Plyler, S. Bouges, C. N. Koval, W. T. Rivers, C. U. Beck, E. I. Chang, R. E. Stroud, R. Mukherjee, and F. G. Spinale Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1394 - H1402. [Abstract] [Full Text] [PDF]

				L. Vinet, P. Rouet-Benzineb, X. Marniquet, N. Pellegrin, L. Mangin, L. Louedec, J.-L. Samuel, and J.-J. Mercadier Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H352 - H360. [Abstract] [Full Text] [PDF]

				F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]

				N. K. LeBrasseur, T.-A. S. Duhaney, D. S. De Silva, L. Cui, P. C. Ip, L. Joseph, and F. Sam Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension Hypertension, September 1, 2007; 50(3): 489 - 496. [Abstract] [Full Text] [PDF]

				T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF]

				P. Krishnamurthy, V. Subramanian, M. Singh, and K. Singh {beta}1 Integrins Modulate {beta}-Adrenergic Receptor-Stimulated Cardiac Myocyte Apoptosis and Myocardial Remodeling Hypertension, April 1, 2007; 49(4): 865 - 872. [Abstract] [Full Text] [PDF]

				R. Martos, J. Baugh, M. Ledwidge, C. O'Loughlin, C. Conlon, A. Patle, S. C. Donnelly, and K. McDonald Diastolic Heart Failure: Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction Circulation, February 20, 2007; 115(7): 888 - 895. [Abstract] [Full Text] [PDF]

				A. N. Panek and M. Bader Matrix Reloaded: The Matrix Metalloproteinase Paradox Hypertension, April 1, 2006; 47(4): 640 - 641. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 47/4/711    most recent 01.HYP.0000208840.30778.00v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsusaka, H. Articles by Tsutsui, H. Search for Related Content PubMed PubMed Citation Articles by Matsusaka, H. Articles by Tsutsui, H. Related Collections Structure Remodeling Animal models of human disease Gene expression Genetically altered mice Hypertrophy Myocardial cardiomyopathy disease Related Article